1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Ledipasvir + sofosbuvir
Trade Name:
Harvoni
Manufacturer/Distributor:
Gilead Sciences Canada Inc.
www.gilead.ca
(905) 363-8008
Classification:
Antiviral agent
ATC Class:
J05AX - Other Antivirals
Status:
active
Notice of Compliance (yyyy/mm/dd):
2014/10/15
Date Marketed in Canada (yyyy/mm/dd):
2015/01/07
Presentation:
Tablet: ledipasvir 90 mg + sofosbuvir 400 mg. DIN: 02432226
Comments:
Harvoni, an antiviral agent, is used for the treatment of chronic hepatitis C virus HCV genotype 1 infection in adults.
The safety and efficacy of Harvoni have not been established in patients with decompensated cirrhosis, or in pediatric patients. Treatment with Harvoni should be initiated and monitored by a physician experienced in the management of CHC. To enrol Harvoni patients in the Gilead Momentum Support Program, fax a completed enrolment form to 1-855-505-5885 or enrol via the Gilead Momentum Support Program online at www.gileadmomentum.com.
Back to:
Drug Product Listings 
